Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 12 of 12 results for apalutamide

  1. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2021
    View recommendations

    Sections for TA741

  2. Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2021
    View recommendations

    Sections for TA740

  3. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA995

  4. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA903

  5. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA951

  6. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA887

  7. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471

    Awaiting development [GID-TA11490] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  9. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued [GID-TA10465]

    Technology appraisal guidance
    Discontinued

  10. Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 July 2021
    View recommendations

    Sections for TA712

  11. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    18 August 2021
    View recommendations

    Sections for TA721

  12. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development [GID-TA11199] Expected publication date: TBC

    Technology appraisal guidance
    In development